Cancer Panels - MEDGENOME

trusight oncology

TSO500

TruSight Oncology 500 offers wide variety of benefits in analyzing multiple tumor variant types in 523 genes in a single assay. It is a next-generation sequencing (NGS) assay that enables comprehensive genomic profiling of tumor samples. The assay is highly effective in identifying all types of relevant DNA and RNA variants in different types of solid tumors including lung, melanoma, ovarian, breast, gastric, bladder, sarcoma etc.

The assay is also highly accurate in measuring immuno-oncology biomarkers such as microsatellite instability (MSI) and tumor mutational burden (TMB).

Download whitepaper

trusight oncology services

Trusight oncology Applications

Solutions for cells, blood, tissues, FFPE, ctDNA with varying quality and quantity inputs

TSO500

Single comprehensive NGS assay to target 523 key immuno-oncology biomarkers for assessment of all DNA and RNA variant types, plus MSI and TMB.
Sample-to-data workflow in 5-7 days using target enrichment on as little as 50 ng of purified DNA and RNA.
Amount of sample needed for ctDNA Purified: >100ng ctDNA in 15-20µl.
TSO 500 data with Dragen and Illumina Connected Insights for the highest accuracy and fastest analysis time.

Get a quote

Bioinformatics Analysis

Trusight oncology analysis

We analyze TSO 500 data via Dragen with Illumina Connected Insights so that you get the highest accuracy variant calls with the fastest analysis time on the market. Take advantage of our compute infrastructure to get comprehensive cancer profiling of your samples.

Detection of SNVs and InDels.
Characterization of CNVs and exon-level CNVs.
Identification of multinucleotide variants (MNVs).
Evaluation of microsatellite instability (MSI).
Measurement of tumor mutational burden (TMB).
Identification of fusion genes and splice variants.

Learn more

Resources

White papers and technical resources

Whitepaper

Comprehensive genomic profiling of clinically relevant cancer genes with Illumina's TruSight Oncology 500 (TSO 500) NGS assay

Download white paper

services

Other services you'll be interested in

Transcriptomics services
WGS/WES services
Immune profiling services

Transcriptomics services

Vast experience and expertise in generating high-quality data from degraded RNA samples.
Supported by custom and advanced bioinformatics analytics.

Learn more

WES/WGS

Cost effective whole genome/exome services with expedited turn-around times.

Learn more

Immuno-oncology solutions

Multi-species (human, mouse, rat and non-human primate) bulk and single cell TCR/BCR sequencing and bioinformatics services.

Learn more

TESTIMONIALS

"Always very quick responses, wonderful turnaround times and exemplary quality of service. Data is always great, and any issues are always resolved. The price is competitive, stable and reliable. There's no problem that the MedGenome team hasn't solved yet."

– Cassie Pond, The Feinstein Institutes for Medical Research

TESTIMONIALS

"We are examining the results. Very exciting. My compliments — you make the best summary report I have seen."

– Dr John Castle, Sr. Director, Bioinformatics, Agenus

TESTIMONIALS

"We have been working with MedGenome on identification of novel oncogenic mutations and exome anlaysis of tumor cells. Our collaboration has been extremely productive. We are extremely happy with their commitment towards research and development in general"

– Dr Krishnaraj Rajalingam, Heisenberg Professor in Cell Biology, Mainz University, Germany

TESTIMONIALS

"We have been working with MedGenome on genomics-based diagnostics and research for many years now. We are extremely happy and pleased with the quality, the skill and the pro-activeness of the firm. No wonder that it has grown to be a leading genomics service provider."

– Dr Radha Rama Venkatesan, Executive Scientific Officer, Molecular Genetics, MDRF

News

Work with the multiomics specialists

Fields marked * are mandatory

Multiomics Services

Research & Pharma Solutions

Resources

About

Contact

MedGenome Appoints Industry Veterans Felix Olale, M.D., Ph.D., as CEO and Jennifer Rose as Chief Commercial Officer to Lead U.S. Expansion

MedGenome, in collaboration with PacBio, announces a de novo genome assembly and annotation grant

MedGenome's genomics solutions for precision medicine

MedGenome, in collaboration with PacBio, announces a de novo genome assembly and annotation grant

Pan-cancer biomarker NGS assay

TSO500

Trusight oncology Applications

TSO500

Trusight oncology analysis

White papers and technical resources

Comprehensive genomic profiling of clinically relevant cancer genes with Illumina's TruSight Oncology 500 (TSO 500) NGS assay

Other services you'll be interested in

Transcriptomics services

WES/WGS

Immuno-oncology solutions

"Always very quick responses, wonderful turnaround times and exemplary quality of service. Data is always great, and any issues are always resolved. The price is competitive, stable and reliable. There's no problem that the MedGenome team hasn't solved yet."

"We are examining the results. Very exciting. My compliments — you make the best summary report I have seen."

"We have been working with MedGenome on identification of novel oncogenic mutations and exome anlaysis of tumor cells. Our collaboration has been extremely productive. We are extremely happy with their commitment towards research and development in general"

"We have been working with MedGenome on genomics-based diagnostics and research for many years now. We are extremely happy and pleased with the quality, the skill and the pro-activeness of the firm. No wonder that it has grown to be a leading genomics service provider."

Featured articles

MedGenome Appoints Industry Veterans Felix Olale, M.D., Ph.D., as CEO and Jennifer Rose as CCO to Lead U.S. Expansion

MedGenome enhances omics insights with in-house PacBio Revio full-service capability

MedGenome announces de novo Genome Assembly and Annotation Grant winners for 2024

MedGenome Inc., honored with the Best of Foster City Award six times in a row

MedGenome appoints Martin Dewhurst as Chairman of Advisory Board

MedGenome achieves 10x Genomics Certified Service provider qualification for single cell sequencing

MedGenome ties-up with Emmes to bridge gaps in rare diseases

MedGenome, in collaboration with PacBio, announces a de novo genome assembly and annotation grant

Gallbladder cancer vaccine candidates identified

Work with the multiomics specialists

Pan-cancer biomarker NGS assay

TSO500

Trusight oncology Applications

TSO500

Trusight oncology analysis

White papers and technical resources

Comprehensive genomic profiling of clinically relevant cancer genes with Illumina's TruSight Oncology 500 (TSO 500) NGS assay

Other services you'll be interested in

Transcriptomics services

WES/WGS

Immuno-oncology solutions

"Always very quick responses, wonderful turnaround times and exemplary quality of service. Data is always great, and any issues are always resolved. The price is competitive, stable and reliable. There's no problem that the MedGenome team hasn't solved yet."

"We are examining the results. Very exciting. My compliments — you make the best summary report I have seen."

"We have been working with MedGenome on identification of novel oncogenic mutations and exome anlaysis of tumor cells. Our collaboration has been extremely productive. We are extremely happy with their commitment towards research and development in general"

"We have been working with MedGenome on genomics-based diagnostics and research for many years now. We are extremely happy and pleased with the quality, the skill and the pro-activeness of the firm. No wonder that it has grown to be a leading genomics service provider."

Featured articles

MedGenome Appoints Industry Veterans Felix Olale, M.D., Ph.D., as CEO and Jennifer Rose as CCO to Lead U.S. Expansion

MedGenome enhances omics insights with in-house PacBio Revio full-service capability

MedGenome announces de novo Genome Assembly and Annotation Grant winners for 2024

MedGenome Inc., honored with the Best of Foster City Award six times in a row

MedGenome appoints Martin Dewhurst as Chairman of Advisory Board

MedGenome achieves 10x Genomics Certified Service provider qualification for single cell sequencing

MedGenome ties-up with Emmes to bridge gaps in rare diseases

MedGenome, in collaboration with PacBio, announces a de novo genome assembly and annotation grant

Gallbladder cancer vaccine candidates identified

Work with the multiomics specialists

Sign up for our newsletter